Effectiveness and Safety Comparison of Lunaphil Ultra (Hyaluronic Acid, by Espad Pharmed Co.) Versus Juvederm Ultra 4® (Hyaluronic Acid, by Allergan Co.) in Nasolabial Folds (NLFs) Management
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Espad Pharmed
Age
30–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects ≥ 30 years of age
Visible bilateral NLFs that were approximately symmetrical and had an equal severity ranging from moderate to severe (assessed at the deepest part)
Able to follow study instructions and likely to complete all required visits
Signed informed consent
You may not be if
History of bleeding disorders or participants receiving or recently exposed (≤ 3 weeks) to continuous treatment with thrombolytics, anticoagulants, platelet inhibitors, or NSAIDs
Acute herpetic eruption
Known susceptibility to keloid formation, hypertrophic scarring or clinically significant skin pigmentation disorders
Known sensitivity to local anesthetics of the amide type (such as lidocaine), history of hypersensitivity to gram-positive bacterial proteins, history of multiple severe allergies, history of anaphylactic shock
Known hypersensitivity to any component of the study products or excipients (like hyaluronic acid)
History of receiving immune therapy or a history of autoimmune disease
History of active chronic debilitating systemic disease
History of connective tissue disease, history of malignancy (except for non-melanoma skin cancer) within the last 5 years
Clinically significant active dermatologic disorders within the last 6 months
Use of oral retinoids, over-the-counter (OTC) or prescription antiwrinkle treatments, microdermabrasion, or chemical peels in the NLF area within the last 4 weeks or intention to use them during the study
Any prior cosmetic procedure or tissue augmentation at the NLF injection site within 1 year before study entry (or intent to undergo such a procedure during the study)